Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001)
Status:
Completed
Trial end date:
2011-04-04
Target enrollment:
Participant gender:
Summary
This study will investigate the safety, side effects and how well the body tolerates MK-5108
as well as determine different doses of MK-5108 in participants with advanced and/or
refractory solid tumors. The corresponding primary hypotheses of this study are that 1)
administration of oral MK-5108 (twice daily for 2 out of 14-21 days) to participants with
advanced and/or refractory solid tumors will be safe and tolerable, and that 2) the spectrum
of side effects observed in these participants after administration of oral MK-5108 alone and
in combination with docetaxel will be dose-dependent and allow for definition of a maximum
tolerated dose (MTD).